NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $5.32 +0.04 (+0.76%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$5.10▼$5.5650-Day Range$5.28▼$9.3152-Week Range$3.16▼$10.13Volume7.95 million shsAverage Volume5.39 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$11.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.6% Upside$11.31 Price TargetShort InterestBearish13.36% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.13Based on 18 Articles This WeekInsider TradingSelling Shares$4.12 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to $0.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.82 out of 5 starsMedical Sector111th out of 896 stocksPharmaceutical Preparations Industry38th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArdelyx has only been the subject of 4 research reports in the past 90 days.Read more about Ardelyx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.36% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Ardelyx has recently increased by 0.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 2.8 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Ardelyx this week, compared to 5 articles on an average week.Search Interest37 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.MarketBeat Follows21 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,117,225.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.36) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesJune 29, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CEO Sells $15,222.90 in StockJune 26, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Insider Robert Blanks Sells 38,000 SharesJuly 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.June 18, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 35,000 SharesJune 8, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Insider Sells $1,032,400.00 in StockJune 6, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 17,872 Shares of StockJuly 5 at 5:50 AM | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Gap Up to $5.28July 5 at 2:10 AM | americanbankingnews.comArdelyx (NASDAQ:ARDX) Price Target Cut to $10.00July 5, 2024 | Golden Crest (Ad)DOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.July 4 at 2:14 AM | americanbankingnews.comPiper Sandler Downgrades Ardelyx (NASDAQ:ARDX) to NeutralJuly 2 at 3:12 PM | globenewswire.comARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law ViolationsJuly 2 at 11:25 AM | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Gap Down to $7.57July 2 at 7:00 AM | globenewswire.comTo Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPAJune 30, 2024 | americanbankingnews.comMichael Raab Sells 2,310 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockJune 30, 2024 | americanbankingnews.comStockNews.com Downgrades Ardelyx (NASDAQ:ARDX) to SellJune 28, 2024 | globenewswire.comArdelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare DisciplinesJune 27, 2024 | seekingalpha.comArdelyx: Potential Headwinds From Weight-Loss Drug AdvancementsJune 27, 2024 | americanbankingnews.comRobert Blanks Sells 38,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockJune 16, 2024 | investorplace.com3 Stocks Under $10 With the Potential to Make You a MillionaireMay 30, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMay 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 24, 2024 | msn.comArdelyx slips as commercial chief departsMay 22, 2024 | benzinga.comLatest News for Ardelyx Stock (NASDAQ:ARDX)May 22, 2024 | globenewswire.comArdelyx to Participate at the 2024 Jefferies Global Healthcare ConferenceMay 21, 2024 | globenewswire.comArdelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsMay 19, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in May 2024May 16, 2024 | globenewswire.comArdelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)See More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/04/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$11.31 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+112.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-41.36% Pretax Margin-40.95% Return on Equity-41.65% Return on Assets-23.08% Debt Debt-to-Equity Ratio0.66 Current Ratio4.53 Quick Ratio4.36 Sales & Book Value Annual Sales$159.11 million Price / Sales7.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book7.39Miscellaneous Outstanding Shares232,700,000Free Float219,902,000Market Cap$1.24 billion OptionableOptionable Beta0.83 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMOPKO HealthNASDAQ:OPK89bioNASDAQ:ETNBFlexion TherapeuticsNASDAQ:FLXNXBiotechNASDAQ:XBITView All CompetitorsInsiders & InstitutionsMichael RaabSold 2,310 sharesTotal: $15,222.90 ($6.59/share)Robert BlanksSold 38,000 sharesTotal: $226,480.00 ($5.96/share)Michael RaabSold 35,000 sharesTotal: $232,750.00 ($6.65/share)Laura A WilliamsSold 145,000 sharesTotal: $1.03 M ($7.12/share)David P RosenbaumSold 17,872 sharesTotal: $125,104.00 ($7.00/share)View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price target for 2024? 9 brokerages have issued 1 year target prices for Ardelyx's stock. Their ARDX share price targets range from $7.00 to $15.00. On average, they expect the company's share price to reach $11.31 in the next twelve months. This suggests a possible upside of 112.6% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2024? Ardelyx's stock was trading at $6.20 at the beginning of the year. Since then, ARDX shares have decreased by 14.2% and is now trading at $5.32. View the best growth stocks for 2024 here. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company earned $46 million during the quarter, compared to analysts' expectations of $36.40 million. Ardelyx had a negative trailing twelve-month return on equity of 41.65% and a negative net margin of 41.36%. Ardelyx's revenue was up 303.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) EPS. What ETF holds Ardelyx's stock? Simplify Propel Opportunities ETF holds 598,000 shares of ARDX stock, representing 4.65% of its portfolio. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDX) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.